

# LET'S LEARN

BOEHRINGER INGELHEIM IN ONCOLOGY

## INVITATION

MAINTAINING MOMENTUM  
IN NSCLC RESEARCH

**Wednesday 6 July 2011**

**Refreshments 18:00-18:20**

**Symposium 18:20-20:00**

The Forum  
Amsterdam RAI Exhibition  
and Convention Centre  
Europaplein 22  
1078 GZ Amsterdam  
The Netherlands

CMI Education Institute  
accredited CME Symposium  
WCLC 2011

Supported by Boeinger Ingelheim

This presentation was selected by the  
14th World Conference on Lung Cancer  
Programme Committee as an independent  
educational activity held in conjunction with  
the 14th World Conference on Lung Cancer.  
This presentation is not sponsored or  
endorsed by the IASLC.

LET'S WORK  
ONCOLOGY FROM BOEHRINGER INGELHEIM



# AGENDA

MAINTAINING MOMENTUM IN NSCLC RESEARCH

## Dear Colleagues

We are delighted to invite you to our CME satellite symposium on "Maintaining Momentum in NSCLC Research" at the IASLC 14th World Conference on Lung Cancer in Amsterdam.

Basic research has provided key insights into the molecular mechanisms driving non-small cell lung cancer (NSCLC) and redundancy within key signalling pathways. These findings highlight the importance of developing single agents with multiple targets and/or successful combination therapies to target these molecular signatures. In recent years, new therapeutic approaches targeting various pathways have been intensively investigated in NSCLC, resulting in median overall survival rates extending beyond 1 year. Specifically, clinicians are becoming increasingly aware of the importance of resistance mutations and the major barrier they represent. Such barriers limit our ability to provide successful long-term treatment of patients with NSCLC.

The goal of this educational symposium is to consider the advances at the forefront of basic research and to demonstrate how momentum can be maintained through the successful translation of these findings into the clinical environment. In particular, this symposium will address effective methods of inhibiting key signalling pathways, including inhibition of the ErbB family of receptors and receptors involved in angiogenesis, while also examining the cell cycle as a promising drug target.

Therefore, during this session we will:

- Present the most recent basic research in key pathways and link this to clinical research in NSCLC
- Consider the latest advances in the treatment of NSCLC
- Identify questions still to be answered in the field of NSCLC and discuss how these questions can best be answered in future studies
- Provide a forum for open discussion between the audience and faculty during Q&A sessions

Our hope is that the educational presentations and active debate session will provide an opportunity to identify key questions that remain unanswered in NSCLC, maintaining momentum and fuelling future research. This programme will be ACCME accredited by CME Education Institute for AMA PRA Category 1 Credit™. International Physicians are formally eligible for AMA PRA Category 1 Credit™.

We hope that you will be able to join us for what we expect to be an engaging and educational session.

**Pieter Postmus**

**Vrije Universiteit Medical Centre, Amsterdam, The Netherlands**

**Chairperson: Pieter Postmus**

**Date: Wednesday 6th July 2011, 18:00-20:00**

**Location: The Forum, Amsterdam RAI Exhibition and Convention Centre**

**18:00 Refreshments**

**18:20 Introduction and welcome**

Pieter Postmus, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands

**18:30 Directions in anti-angiogenesis: Are we making progress?**

Natasha Leighl, Princess Margaret Hospital, Toronto, Canada

**18:55 ErbB family-driven cancers - overcoming the limitations of reversible EGFR TKIs**


James Spicer, King's College London at Guy's Hospital, London, UK

**19:20 Targeting the cell cycle and its potential for impact in NSCLC**

Wilfried Eberhardt, West German Tumour Centre, University Hospital Essen of University Duisburg-Essen, Essen, Germany

**19:45 Debate**

**20:00 Meeting close**



### **Accreditation Statement**


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CMI Education Institute and Ogilvy Healthworld Medical Education. CMI Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

### **Credit Designation**

CMI Education Institute designates this educational live activity for a maximum of 1.5 *AMA PRA category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **International CME**

International Physicians are formally eligible for *AMA PRA Category 1 Credit*<sup>™</sup>.



**LET'S WORK**  
ONCOLOGY FROM BOEHRINGER INGELHEIM

